- Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
-
Kim SH, Jo EJ, Mok J, Lee K, Kim KU, Park HK, Lee MK, Eom JS, Kim MH
- KMID: 2539974
- Korean J Intern Med.
- 2023 Mar;38(2):218-225.
- doi: 10.3904/kjim.2022.361
Background/Aims: Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce. Methods: This retrospective study included 89... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of the adverse effects of cancer immunotherapy with a focus on the respiratory and nervous systems
-
Park SE
- KMID: 2539907
- J Korean Med Assoc.
- 2023 Feb;66(2):116-122.
- doi: 10.5124/jkma.2023.66.2.116
Background: The incidence of adverse toxic reactions to immunotherapy using immune checkpoint inhibitors is 2-10% in the respiratory system and 3.9% to 12% in the neurologic system. The severity of... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of the adverse effects of cancer immunotherapy with a focus on the gastrointestinal and hepatic systems
-
Cheon J
- KMID: 2539906
- J Korean Med Assoc.
- 2023 Feb;66(2):112-115.
- doi: 10.5124/jkma.2023.66.2.112
Background: Immunotherapy has become established as a new cancer treatment that enhances patients’ immune systems’ ability to fight cancer. Immune checkpoint inhibitors (ICI) have demonstrated remarkable benefits in the treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Progress in Immunotherapy for Gastric Cancer
-
Yoon J, Kim TY, Oh DY
- KMID: 2539472
- J Gastric Cancer.
- 2023 Jan;23(1):207-223.
- doi: 10.5230/jgc.2023.23.e10
Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide. Under the standard of care, patients with advanced GC (AGC) have a median survival time of approximately 12–15... -
- CITED
-
- Close
- SHARE
-
- Close
- Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
-
Lim S, Park JH, Chang H
- KMID: 2537524
- Investig Clin Urol.
- 2023 Jan;64(1):74-81.
- doi: 10.4111/icu.20220031
Purpose: Programmed cell death protein 1 (PD-1) and ligand programmed death ligand 1 (PD-L1) are important immune-suppressive regulators in the tumor microenvironment. A vaccine-induced immune effect on tumor cells is... -
- CITED
-
- Close
- SHARE
-
- Close
- Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy
-
Fomchenko EI, Bayley JC, Alvarez-Breckenridge C, Rhines LD, Tatsui CE
- KMID: 2537362
- Neurospine.
- 2022 Dec;19(4):978-993.
- doi: 10.14245/ns.2244290.145
Metastatic involvement of the spine is a common complication of systemic cancer progression. Surgery and external beam radiotherapy are palliative treatment modalities aiming to preserve neurological function, control pain and... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful treatment of post–COVID-19 acute disseminated encephalomyelitis with urgent immunotherapy and neurointensive management: a case report
-
Lee JS, Kim HJ, Kim JG
- KMID: 2538771
- J Neurocrit Care.
- 2022 Dec;15(2):131-135.
- doi: 10.18700/jnc.220078
Background: Acute disseminated encephalomyelitis (ADEM)-like white matter disease, a rare complication of coronavirus disease 2019 (COVID-19), is a potentially life-threatening neurological disorder. The objective of this study was to report... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Progress in Immunotherapy for Metastatic Colorectal Cancer
-
Kim SJ, Lee J
- KMID: 2536423
- J Dig Cancer Res.
- 2022 Dec;10(2):65-73.
- doi: 10.52927/jdcr.2022.10.2.65
A breakthrough in immunotherapy has changed the outlook for metastatic colorectal cancer (mCRC) treatment as the immune surveillance evasion mechanism of tumor cells has been continuously elucidated. Immune checkpoint inhibitors... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
-
Kim N, Lee ES, Won SE, Yang M, Lee AJ, Shin Y, Ko Y, Pyo J, Park HJ, Kim KW
- KMID: 2534421
- Korean J Radiol.
- 2022 Nov;23(11):1089-1101.
- doi: 10.3348/kjr.2022.0225
Immunotherapy has revolutionized and opened a new paradigm for cancer treatment. In the era of immunotherapy and molecular targeted therapy, precision medicine has gained emphasis, and an early response assessment... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-world cases with wheat oral immunotherapy in children with multiple food anaphylaxis
-
Han H, Lee H, Youm S, Lee S, Lee C, Lee J
- KMID: 2534611
- Allergy Asthma Respir Dis.
- 2022 Oct;10(4):222-228.
- doi: 10.4168/aard.2022.10.4.222
Providing a protocol in the case of multiple food allergies is difficult although the demand of immunotherapy for patients with wheat anaphylaxis is increasing. This case series study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of a house dust mite-induced mouse model for allergen-specific immunotherapy in allergic rhinitis
-
Kim SM, Kim JA, Kim HS, Yoon JS, Kim HH, Chun YH
- KMID: 2534606
- Allergy Asthma Respir Dis.
- 2022 Oct;10(4):195-201.
- doi: 10.4168/aard.2022.10.4.195
Purpose: Allergen-specific immunotherapy (AIT) is the only known curative treatment for allergic diseases. Recently, novel immunotherapies have been developed to overcome the inconvenience and adverse reactions associated with conventional AIT.... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody
-
Kim SH, Park JH, Lee SJ, Lee HS, Jung JK, Lee YR, Cho HI, Kim JK, Kim K, Park CS, Lee CK
- KMID: 2536269
- Immune Netw.
- 2022 Oct;22(5):e42.
- doi: 10.4110/in.2022.22.e42
Vaccination with tumor peptide epitopes associated with MHC class I molecules is an attractive approach directed at inducing tumor-specific CTLs. However, challenges remain in improving the therapeutic efficacy of peptide... -
- CITED
-
- Close
- SHARE
-
- Close
- Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes
-
Park JH, Park YM, Kim DH, Kim SH, Kim HR, Koh YW
- KMID: 2534450
- Korean J Otorhinolaryngol-Head Neck Surg.
- 2022 Oct;65(10):610-616.
- doi: 10.3342/kjorl-hns.2022.00283
Background and Objectives We analyzed surgical outcomes, perioperative complications, and mortality in head and neck squamous cell carcinoma (HNSCC) in patients who underwent curative surgery following neoadjuvant immunotherapy. Subjects and Method... -
- CITED
-
- Close
- SHARE
-
- Close
- Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development
-
Park CO, Kim HL, Park JW
- KMID: 2533366
- Yonsei Med J.
- 2022 Oct;63(10):881-891.
- doi: 10.3349/ymj.2022.0092
Transdermal drug delivery systems (TDDSs) overcome the hurdle of an intact skin barrier by penetrating the skin to allow molecules through. These systems reduce side effects associated with conventional hypodermic... -
- CITED
-
- Close
- SHARE
-
- Close
- Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review
-
Kim TJ, Lee YH, Koo KC
- KMID: 2532882
- Investig Clin Urol.
- 2022 Sep;63(5):486-498.
- doi: 10.4111/icu.20220103
In the clinical setting of renal cell carcinoma (RCC), immune reactions such as tumor-specific T cell responses can be spontaneous events or can be elicited by checkpoint inhibitors, cytokines, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Bispecific Antibody-Bound T Cells as a Novel Anticancer Immunotherapy
-
Cho J, Tae N, Ahn JH, Chang SY, Ko HJ, Kim DH
- KMID: 2532874
- Biomol Ther.
- 2022 Sep;30(5):418-426.
- doi: 10.4062/biomolther.2022.015
Chimeric antigen receptor T (CAR-T) cell therapy is one of the promising anticancer treatments. It shows a high overall response rate with complete response to blood cancer. However, there is... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma
-
Kim DH
- KMID: 2534236
- J Liver Cancer.
- 2022 Sep;22(2):93-102.
- doi: 10.17998/jlc.2022.03.28
Interventional oncology (IO) local therapies of hepatocellular carcinoma (HCC) can activate anti-cancer immunity and it is potentially leading to an anti-cancer immunity throughout the body. For the development of an... -
- CITED
-
- Close
- SHARE
-
- Close
- Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?
-
Choi JD, Cho JM, Yoo TK
- KMID: 2533085
- Korean J Urol Oncol.
- 2022 Aug;20(3):139-150.
- doi: 10.22465/kjuo.2022.20.3.139
Cytoreductive nephrectomy (CN) has long been the standard of care for patients with metastatic renal cell carcinoma (mRCC) since 2 clinical trials revealed its role during the cytokines era. With... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Subclinical Sensitization with Diphenylcyclopropenone in Children with Alopecia Areata: A Retrospective Study
-
Lee SH, Lee CH, Kang H, Lee WS
- KMID: 2532296
- Korean J Dermatol.
- 2022 Jul;60(6):371-377.
Background: Contact immunotherapy with diphenylcyclopropenone is one of the first-line treatments for extensive alopecia areata, despite its adverse effects (AEs). Objective: This study aimed to investigate whether a modified contact immunotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
-
Ahn J, Shin C, Kim YS, Park JS, Jeun SS, Ahn S
- KMID: 2532243
- Brain Tumor Res Treat.
- 2022 Jul;10(3):135-143.
- doi: 10.14791/btrt.2022.0010
Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have... -
- CITED
-
- Close
- SHARE
-
- Close
